Mainz Biomed (MYNZ) Competitors $1.69 -0.03 (-1.74%) Closing price 04:00 PM EasternExtended Trading$1.66 -0.03 (-2.07%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MYNZ vs. JATT, RNTX, TENX, NNVC, LGVN, BDRX, FBLG, CASI, AYTU, and QTTBShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include JATT Acquisition (JATT), Rein Therapeutics (RNTX), Tenax Therapeutics (TENX), NanoViricides (NNVC), Longeveron (LGVN), Biodexa Pharmaceuticals (BDRX), FibroBiologics (FBLG), CASI Pharmaceuticals (CASI), Aytu BioPharma (AYTU), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Its Competitors JATT Acquisition Rein Therapeutics Tenax Therapeutics NanoViricides Longeveron Biodexa Pharmaceuticals FibroBiologics CASI Pharmaceuticals Aytu BioPharma Q32 Bio JATT Acquisition (NYSE:JATT) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership. Does the media prefer JATT or MYNZ? In the previous week, Mainz Biomed had 4 more articles in the media than JATT Acquisition. MarketBeat recorded 4 mentions for Mainz Biomed and 0 mentions for JATT Acquisition. Mainz Biomed's average media sentiment score of 0.46 beat JATT Acquisition's score of 0.00 indicating that Mainz Biomed is being referred to more favorably in the news media. Company Overall Sentiment JATT Acquisition Neutral Mainz Biomed Neutral Is JATT or MYNZ more profitable? Mainz Biomed's return on equity of 0.00% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Mainz Biomed N/A N/A N/A Do institutionals and insiders hold more shares of JATT or MYNZ? 48.0% of JATT Acquisition shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable earnings & valuation, JATT or MYNZ? JATT Acquisition has higher earnings, but lower revenue than Mainz Biomed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AMainz Biomed$890K8.70-$21.65M-$65.60-0.03 Do analysts recommend JATT or MYNZ? Mainz Biomed has a consensus target price of $14.00, suggesting a potential upside of 728.40%. Given Mainz Biomed's stronger consensus rating and higher possible upside, analysts clearly believe Mainz Biomed is more favorable than JATT Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mainz Biomed 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryMainz Biomed beats JATT Acquisition on 7 of the 11 factors compared between the two stocks. Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.87M$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-0.0320.4930.2925.74Price / Sales8.70356.37462.79115.73Price / CashN/A43.0338.2159.48Price / Book0.658.608.826.15Net Income-$21.65M-$54.65M$3.25B$265.06M7 Day Performance16.55%5.43%4.05%2.80%1 Month Performance-8.65%6.75%4.32%1.68%1 Year Performance-86.63%31.59%36.25%29.59% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.6547 of 5 stars$1.69-1.7%$14.00+728.4%-87.7%$7.87M$890K-0.0330News CoverageShort Interest ↑JATTJATT AcquisitionN/A$1.50+7.1%N/A-55.3%$25.88MN/A0.003Gap UpHigh Trading VolumeRNTXRein TherapeuticsN/A$1.12+0.9%N/AN/A$25.81MN/A-0.399News CoverageEarnings ReportTENXTenax Therapeutics1.9721 of 5 stars$6.18-0.6%$17.50+183.2%+46.7%$25.65MN/A-2.499News CoverageEarnings ReportAnalyst ForecastNNVCNanoViricides0.3136 of 5 stars$1.59+0.6%N/A-13.8%$25.55MN/A-2.2120LGVNLongeveron3.7721 of 5 stars$1.71+4.6%$8.67+406.8%-67.7%$25.53M$2.23M-0.2720News CoverageEarnings ReportBDRXBiodexa Pharmaceuticals1.0239 of 5 stars$6.98+4.2%N/AN/A$25.51MN/A0.0020Positive NewsShort Interest ↓FBLGFibroBiologics3.2231 of 5 stars$0.61-6.2%$13.00+2,036.4%-68.7%$24.15MN/A-1.6910Short Interest ↑Gap DownCASICASI Pharmaceuticals4.1583 of 5 stars$1.95+51.2%$4.00+105.1%-71.8%$23.99M$28.54M-0.76180News CoverageUpcoming EarningsGap DownHigh Trading VolumeAYTUAytu BioPharma3.7897 of 5 stars$2.65+10.4%$10.00+277.4%-5.3%$23.80M$81M-3.68160News CoverageQTTBQ32 Bio2.7917 of 5 stars$1.93-3.5%$12.17+530.4%-94.9%$23.54MN/A-0.3939Short Interest ↓ Related Companies and Tools Related Companies JATT Acquisition Alternatives Rein Therapeutics Alternatives Tenax Therapeutics Alternatives NanoViricides Alternatives Longeveron Alternatives Biodexa Pharmaceuticals Alternatives FibroBiologics Alternatives CASI Pharmaceuticals Alternatives Aytu BioPharma Alternatives Q32 Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYNZ) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access